SPRB

0.40

4.68% 0.0179

Handel nachbörslich: .40

Spruce Biosciences Inc (SPRB)

Überblick Nachrichten Preisverlauf Financials Forum Prognose

Schlusskurs vom Vortag:

$0.3821

Offen:

$0.3821

24-Stunden-Volumen:

320.82K

Relative Volume:

0.57

Marktkapitalisierung:

$16.52M

Einnahmen:

$9.57M

Nettoeinkommen (Verlust:

$-43.11M

KGV:

-0.2395

EPS:

-1.67

Netto-Cashflow:

$-49.54M

1W Leistung:

+4.38%

1M Leistung:

-18.37%

6M Leistung:

-24.53%

1J Leistung:

-75.61%

1-Tages-Spanne:

$0.373

$0.40

1-Wochen-Bereich:

$0.373

$0.418

52-Wochen-Spanne:

$0.37

$5.95

Spruce Biosciences Inc Stock (SPRB) Company Profile

Firmenname

Spruce Biosciences Inc

Sektor

Healthcare (1176)

Branche

Biotechnology (673)

Telefon

(415) 655-4168

Adresse

611 GATEWAY BOULEVARD, SUITE 740, SOUTH SAN FRANCISCO

Mitarbeiter

Twitter

Nächster Verdiensttermin

2024-11-11

Neueste SEC-Einreichungen

SPRB's Discussions on Twitter

Vergleichen Sie SPRB mit anderen Aktien

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
SPRB Spruce Biosciences Inc	0.40	16.52M	9.57M	-43.11M	-49.54M	-1.03
VRTX Vertex Pharmaceuticals Inc	397.27	102.31B	10.63B	-479.80M	-1.35B	-1.99
REGN Regeneron Pharmaceuticals Inc	701.85	77.13B	13.85B	4.65B	3.32B	40.41
ARGX Argen X Se Adr	623.82	37.30B	1.86B	-40.29M	-1.28B	-0.85
ALNY Alnylam Pharmaceuticals Inc	245.44	31.66B	2.09B	-332.26M	16.06M	-2.62
BNTX Biontech Se Adr	113.08	27.11B	3.30B	-501.07M	1.03B	-2.1146

Spruce Biosciences Inc Stock (SPRB) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2024-12-11	Herabstufung	JMP Securities	Mkt Outperform → Mkt Perform
2024-12-11	Herabstufung	Oppenheimer	Outperform → Perform
2024-03-14	Herabstufung	Guggenheim	Buy → Neutral
2024-03-14	Herabstufung	H.C. Wainwright	Buy → Neutral
2024-03-14	Herabstufung	Ladenburg Thalmann	Buy → Neutral
2024-03-14	Herabstufung	Leerink Partners	Outperform → Market Perform
2024-03-14	Herabstufung	RBC Capital Mkts	Outperform → Sector Perform
2024-02-21	Eingeleitet	Guggenheim	Buy
2021-12-17	Eingeleitet	Oppenheimer	Outperform
2021-12-10	Eingeleitet	The Benchmark Company	Speculative Buy
2021-11-16	Herabstufung	SVB Leerink	Outperform → Mkt Perform
2021-07-19	Eingeleitet	H.C. Wainwright	Buy
2021-04-26	Fortgesetzt	Credit Suisse	Outperform
2020-11-03	Eingeleitet	Cowen	Outperform
2020-11-03	Eingeleitet	Credit Suisse	Outperform
2020-11-03	Eingeleitet	RBC Capital Mkts	Outperform
2020-11-03	Eingeleitet	SVB Leerink	Outperform

Alle ansehen

Spruce Biosciences Inc Aktie (SPRB) Neueste Nachrichten

Dec 20, 2024

Neurocrine Biosciences launches Crenessity in USA - The Pharma Letter

Dec 20, 2024

HC Wainwright Has Bullish Estimate for SPRB FY2024 Earnings - Defense World

Dec 20, 2024

Dec 17, 2024

Spruce Biosciences (NASDAQ:SPRB) Given “Neutral” Rating at HC Wainwright - Defense World

Dec 17, 2024

Dec 16, 2024

Spruce Biosciences (SPRB) Upgraded to Buy: Here's Why - MSN

Dec 16, 2024

Spruce Biosciences' SWOT analysis: tildacerfont trials shape stock outlook - Investing.com

Dec 16, 2024

Dec 15, 2024

Spruce Biosciences’ (SPRB) Neutral Rating Reiterated at Guggenheim - Defense World

Dec 15, 2024

Dec 14, 2024

FY2024 Earnings Forecast for SPRB Issued By Leerink Partnrs - Defense World

Dec 14, 2024

Dec 13, 2024

Needham & Company LLC Reiterates Buy Rating for Recursion Pharmaceuticals (NASDAQ:RXRX) - Defense World

Dec 13, 2024

Rigel Pharmaceuticals’ (RIGL) “Buy” Rating Reiterated at HC Wainwright - Defense World

Dec 13, 2024

Spruce Biosciences (NASDAQ:SPRB) Earns “Market Perform” Rating from Oppenheimer - Defense World

Dec 13, 2024

Mizuho Cuts Revance Therapeutics (NASDAQ:RVNC) Price Target to $3.10 - Defense World

Dec 13, 2024

Spruce Biosciences (NASDAQ:SPRB) Earns “Market Perform” Rating from JMP Securities - Defense World

Dec 13, 2024

Spruce Biosciences (NASDAQ:SPRB) Earns “Sector Perform” Rating from Royal Bank of Canada - Defense World

Dec 13, 2024

Telsey Advisory Group Increases Stitch Fix (NASDAQ:SFIX) Price Target to $6.00 - Defense World

Dec 13, 2024

Sirius XM (NASDAQ:SIRI) Earns “Buy” Rating from Guggenheim - Defense World

Dec 13, 2024

Wells Fargo & Company Initiates Coverage on Summit Therapeutics (NASDAQ:SMMT) - Defense World

Dec 13, 2024

Wells Fargo & Company Reaffirms “Equal Weight” Rating for RxSight (NASDAQ:RXST) - Defense World

Dec 13, 2024

Solid Biosciences (NASDAQ:SLDB) Research Coverage Started at JMP Securities - Defense World

Dec 13, 2024

Citizens Jmp Downgrades Spruce Biosciences (NASDAQ:SPRB) to Hold - Defense World

Dec 13, 2024

SPRB stock touches 52-week low at $0.41 amid market challenges - Investing.com Australia

Dec 13, 2024

Dec 12, 2024

Clinical Trials News Live Feed - StockTitan

Dec 12, 2024

Arnold Schwarzenegger is joining a Fortune 500 company to solve a great problem of his generation - Yahoo Finance

Dec 12, 2024

SPRB stock touches 52-week low at $0.41 amid market challenges By Investing.com - Investing.com South Africa

Dec 12, 2024

Dec 11, 2024

Spruce stock outlook reduced as tildacerfont falls short, company explores alternatives - Investing.com Canada

Dec 11, 2024

Oppenheimer Downgrades Spruce Biosciences (SPRB) - MSN

Dec 11, 2024

Spruce Biosciences stock downgraded after trial miss By Investing.com - Investing.com Canada

Dec 11, 2024

Penny Stock Spruce Biosciences Winds Down Tildacerfont Studies For Rare Genetic Disorder - Yahoo Finance

Dec 11, 2024

Spruce Biosciences stock downgraded after trial miss - Investing.com

Dec 11, 2024

Spruce Biosciences downgraded to Perform from Outperform at Oppenheimer - TipRanks

Dec 11, 2024

Oppenheimer cuts Spruce Biosciences to perform By Investing.com - Investing.com UK

Dec 11, 2024

Dec 10, 2024

Spruce Biosciences Announces Topline Results from CAHmelia-204 in Adult CAH and CAHptain-205 in Adult and Pediatric CAH - The Bakersfield Californian

Dec 10, 2024

Congenital Adrenal Hyperplasia Clinical Trials 2024: EMA, - openPR

Dec 10, 2024

Company News for Dec 10, 2024 - Yahoo Finance

Dec 10, 2024

Spruce Biosciences Halts CAH Drug Program After Phase 2 Trial Misses Key Endpoint - StockTitan

Dec 10, 2024

Dec 09, 2024

Layoff Tracker: CDMOs Cut Costs With AmplifyBio and Resilience Layoffs - BioSpace

Dec 09, 2024

Dec 06, 2024

UBS Initiates Coverage of Glaukos (GKOS) with Buy Recommendation - MSN

Dec 06, 2024

Dec 05, 2024

Spruce Biosciences' SWOT analysis: tildacerfont trials key for CAH stock By Investing.com - Investing.com UK

Dec 05, 2024

Dec 03, 2024

Spruce Biosciences stock holds potential as Oppenheimer targets upcoming Phase 2b results - Investing.com Australia

Dec 03, 2024

Dec 02, 2024

Spruce Biosciences stock holds potential as Oppenheimer targets upcoming Phase 2b results By Investing.com - Investing.com South Africa

Dec 02, 2024

Nov 27, 2024

PTAB Finds Hormone Treatment Patent Claims Invalid - Law360

Nov 27, 2024

Nov 21, 2024

Spruce Biosciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com

Nov 21, 2024

Nov 19, 2024

Supplementary Review: IBEX Limited (IBEX), November 19, 2024 - MSN

Nov 19, 2024

Nov 15, 2024

ARMISTICE CAPITAL, LLC Acquires New Stake in Spruce Biosciences Inc - GuruFocus.com

Nov 15, 2024

Nov 14, 2024